Physician profile
Truly Peterson
NPI 1982643680
$726.17
in general payments reported to CMS, 2019-2025
15 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $350 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.89 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $89.49 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $87.15 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $70.20 | 2025 | Airsupra, Farxiga, Breztri |
| Shield Therapeutics INC | $63.39 | 2024 | |
| Pfizer INC. | $57.49 | 2024 | |
| Acadia Pharmaceuticals INC | $42.16 | 2024 | Nuplazid |
| Merck Sharp & Dohme LLC | $33.14 | 2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $21.50 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $19.44 | 2025 | Gemtesa |
| Tms Neurohealth Centers INC. | $18.94 | 2025 | Tms Neurohealth Centers INC. |
| Medtronic, INC. | $17.19 | 2025 | Vanta Adaptivestim |
| Currax Pharmaceuticals LLC | $17.17 | 2025 | Contrave |
| Idorsia Pharmaceuticals US INC | $15.25 | 2024 | Quviviq |
| Abbvie INC. | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Truly Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.